Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
Journal
Therapeutics and Clinical Risk Management
Journal Volume
17
Pages
193-207
Date Issued
2021
Author(s)
Abstract
mutation testing upon diagnosing HR+/HER2- advanced breast cancer, which can be done using either tumor tissue or circulating tumor DNA. With appropriate toxicity management and patient selection using validated testing methods, all eligible patients can potentially benefit from this new treatment. Further clinical trials to assess combinations of hormone therapy with PI3K, AKT, mTOR, or CDK 4/6 inhibitors, or studies in men and women with other breast subtypes are ongoing.
SDGs
Publisher
Dove Medical Press Ltd
Type
journal article